Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16040412 | 1.00 | SYK (0.38) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL16040414 | 1.00 | SYK (0.38) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL30790693 | 0.87 | SYK (0.43) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL29578990 | 0.87 | SYK (0.43) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL16040024 | 0.87 | SYK (0.43) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL16038633 | 0.87 | SYK (0.43) | SYKKDRTBK1IKBKELRRK2 | |
| SCHEMBL16040755 | 0.86 | MAPK1 (0.43) | SYKTBK1IKBKE | |
| SCHEMBL16079599 | 0.86 | MAPK1 (0.43) | SYKTBK1IKBKE | |
| SCHEMBL16040749 | 0.86 | MAPK1 (0.43) | SYKTBK1IKBKE | |
| SCHEMBL30790689 | 0.86 | MAPK1 (0.43) | SYKTBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| CN-111741955-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2970218-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275059-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275059-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | SYK 3586/4885KDR 1962/4885TBK1 426/4885 |
| US-11813267-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SYK 2672/4885KDR 1164/4885TBK1 506/4885 |
| US-20140275059-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SYK 2672/4885KDR 1164/4885TBK1 506/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | SYK 2655/4885KDR 965/4885TBK1 475/4885 |
| US-20140275024-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | SYK 2672/4885KDR 1164/4885TBK1 506/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | SYK 2953/4885KDR 1283/4885TBK1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.